CN107303278A - 一种hc‑1119固体分散体及其制备方法 - Google Patents
一种hc‑1119固体分散体及其制备方法 Download PDFInfo
- Publication number
- CN107303278A CN107303278A CN201710278273.6A CN201710278273A CN107303278A CN 107303278 A CN107303278 A CN 107303278A CN 201710278273 A CN201710278273 A CN 201710278273A CN 107303278 A CN107303278 A CN 107303278A
- Authority
- CN
- China
- Prior art keywords
- solid dispersions
- parts
- acid
- cellulose
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
处方1(mg) | |
HC-1119 | 80 |
Syloidy244fp | 80 |
HPMCAS | 54 |
乳糖 | 233 |
微晶纤维素 | 120 |
交联羧甲基纤维素钠 | 30 |
硬脂酸镁 | 3 |
总计 | 600 |
处方1(1000片) | 处方2(1000片) | |
HC-1119 | 80g | 80g |
Syloid244FP | 120g | 80g |
丙酮 | 240ml | 160ml |
处方1 | 含量mg/g | 有机残留 | 杂质B |
检测项目 | 417.93mg/g | 0.13% | 0.034% |
HC-1119 | 80mg |
Neusilin US2 | 320mg |
HPMCAS | 27mg |
丙酮 | 1.07ml |
Claims (13)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016102604467 | 2016-04-25 | ||
CN201610260446 | 2016-04-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107303278A true CN107303278A (zh) | 2017-10-31 |
CN107303278B CN107303278B (zh) | 2020-11-13 |
Family
ID=60151111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710278273.6A Active CN107303278B (zh) | 2016-04-25 | 2017-04-25 | 一种hc-1119固体分散体及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107303278B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108175751A (zh) * | 2018-01-22 | 2018-06-19 | 宁夏医科大学 | 一种蟾毒配基固体分散体及其制备方法 |
WO2019218979A1 (zh) * | 2018-05-14 | 2019-11-21 | 成都海创药业有限公司 | 一种hc-1119制剂及其制备方法和用途 |
CN112791056A (zh) * | 2021-01-22 | 2021-05-14 | 河北农业大学 | 一种氟苯尼考固体分散体及其制备方法 |
RU2777008C2 (ru) * | 2018-05-14 | 2022-08-02 | Хинова Фармасьютикалс Инк. | Состав hc-1119, способ его получения и применение |
CN115052586A (zh) * | 2020-02-07 | 2022-09-13 | 拜耳公司 | 包含瑞戈非尼和稳定剂的药物组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101066264A (zh) * | 2007-06-12 | 2007-11-07 | 杨喜鸿 | 奥美沙坦酯的固体分散体及其制备方法和药物应用 |
CN101123951A (zh) * | 2004-08-31 | 2008-02-13 | 辉瑞产品公司 | 包括低溶解性药物和聚合物的药物剂型 |
WO2013087004A1 (zh) * | 2011-12-14 | 2013-06-20 | Chen Yuanwei | 咪唑二酮类化合物及其用途 |
KR101301700B1 (ko) * | 2012-11-14 | 2013-08-30 | (주)비씨월드제약 | 용해도 및 안정성이 개선된 리팜피신을 포함하는 결핵 치료용 약학 조성물 및 이의 제조방법 |
-
2017
- 2017-04-25 CN CN201710278273.6A patent/CN107303278B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101123951A (zh) * | 2004-08-31 | 2008-02-13 | 辉瑞产品公司 | 包括低溶解性药物和聚合物的药物剂型 |
CN101066264A (zh) * | 2007-06-12 | 2007-11-07 | 杨喜鸿 | 奥美沙坦酯的固体分散体及其制备方法和药物应用 |
WO2013087004A1 (zh) * | 2011-12-14 | 2013-06-20 | Chen Yuanwei | 咪唑二酮类化合物及其用途 |
KR101301700B1 (ko) * | 2012-11-14 | 2013-08-30 | (주)비씨월드제약 | 용해도 및 안정성이 개선된 리팜피신을 포함하는 결핵 치료용 약학 조성물 및 이의 제조방법 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108175751A (zh) * | 2018-01-22 | 2018-06-19 | 宁夏医科大学 | 一种蟾毒配基固体分散体及其制备方法 |
RU2798663C2 (ru) * | 2018-03-29 | 2023-06-23 | Хинова Фармасьютикалс Инк. | Дейтерированные имидазолидиндионовые соединения и их применения |
WO2019218979A1 (zh) * | 2018-05-14 | 2019-11-21 | 成都海创药业有限公司 | 一种hc-1119制剂及其制备方法和用途 |
KR20210006949A (ko) * | 2018-05-14 | 2021-01-19 | 하이노바 파마슈티컬스 인코포레이티드 | Hc-1119 제제 및 그 제조방법 및 용도 |
JP2021523195A (ja) * | 2018-05-14 | 2021-09-02 | ヒノバ ファーマシューティカルズ インコーポレイテッド | Hc−1119製剤及びその製造方法と使用 |
RU2777008C2 (ru) * | 2018-05-14 | 2022-08-02 | Хинова Фармасьютикалс Инк. | Состав hc-1119, способ его получения и применение |
KR102542275B1 (ko) * | 2018-05-14 | 2023-06-12 | 하이노바 파마슈티컬스 인코포레이티드 | Hc-1119 제제 및 그 제조방법 및 용도 |
JP7301883B2 (ja) | 2018-05-14 | 2023-07-03 | ヒノバ ファーマシューティカルズ インコーポレイテッド | Hc-1119製剤及びその製造方法と使用 |
CN115052586A (zh) * | 2020-02-07 | 2022-09-13 | 拜耳公司 | 包含瑞戈非尼和稳定剂的药物组合物 |
CN112791056A (zh) * | 2021-01-22 | 2021-05-14 | 河北农业大学 | 一种氟苯尼考固体分散体及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN107303278B (zh) | 2020-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105358535B (zh) | 恩杂鲁胺制剂 | |
KR101157220B1 (ko) | 리팍시민을 포함하는 위내성 약학적 제제 | |
CN101636152B (zh) | 含有西洛他唑的控释制剂及其制备方法 | |
CN1496738B (zh) | 具有高生物利用率的非诺贝特药物组合物及其制备方法 | |
AU2017376544B2 (en) | Oral preparation of glucokinase activator and preparation method therefor | |
ES2731881T3 (es) | Composiciones que comprenden compuestos activos lipófilos y método para su preparación | |
US20180008539A1 (en) | Gastroretentive extended release suspension compositions | |
JP7124107B2 (ja) | 多孔性シリカ粒子組成物 | |
CN107303278A (zh) | 一种hc‑1119固体分散体及其制备方法 | |
CN106102716A (zh) | 雄激素受体拮抗剂的固体药物组合物 | |
US20150342895A1 (en) | Hydroxyalkyl cellulose | |
CN102805733A (zh) | 颗粒制剂及其制造方法 | |
CN103919715A (zh) | 含有甘磷酸胆碱或其盐的控释药物组合物及其制备方法 | |
JP2018516900A (ja) | カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤 | |
JP2007211006A (ja) | 溶出安定性を有するコーティング固形製剤 | |
JP2008539231A (ja) | 濡れ性の向上した、医薬として許容され得る可塑剤が組み込まれたセルロース系フィルム | |
WO2016139683A2 (en) | Pharmaceutical compositions of lurasidone and process for preparing the same | |
JP2006298811A (ja) | ゲル化抑制製剤の設計 | |
JP5392892B2 (ja) | リン酸水素カルシウムからなる球状粒子 | |
JPH09132522A (ja) | 発泡性組成物およびその製造方法 | |
CN103860464B (zh) | 一种抗过敏药物缓释混悬剂及其制备方法 | |
CN102349889B (zh) | 一种含有决奈达隆的组合物 | |
CN104093400A (zh) | 稳定的无定形雷特格韦钾盐预混料及其制备方法 | |
US20150328316A1 (en) | Magnesium hydroxide carbonate as excipient in pharmaceutical preparations having improved release of active ingredient | |
BR112020002705A2 (pt) | composições extrudadas de enzalutamida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20171031 Assignee: Sichuan Haisco Pharmaceutical Co.,Ltd. Assignor: Chengdu SeaBird pharmaceutcal corporation, Ltd Contract record no.: 2019510000018 Denomination of invention: A HC-1119 solid dispersion and its preparation method License type: Exclusive License Record date: 20190604 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: No.2 and No.3, floor 4, building 1, Rongyao building, No.5 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610000 Patentee after: Haichuang Pharmaceutical Co., Ltd Address before: No. 801, C1 incubation building, Tianfu Life Science Park, 88 Keyuan South Road, high tech Zone, Chengdu, Sichuan 610041 Patentee before: Chengdu Haichuang Pharmaceutical Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: SICHUAN HAISCO PHARMACEUTICAL Co.,Ltd. Assignor: Chengdu Haichuang Pharmaceutical Co.,Ltd. Contract record no.: 2019510000018 Date of cancellation: 20210312 |
|
EC01 | Cancellation of recordation of patent licensing contract |